ASCO GU 2022: Abstracten gerelateerd aan prostaatkanker gepresenteerd op het American Society of Clinical Oncology Genitourinary Cancers Symposium van 17 tot 19 februari 2022

Als donateur kunt u ook korting krijgen bij verschillende bedrijven. En we hebben een ANBI status

En als donateur kunt u ook korting krijgen bij verschillende bedrijven, waaronder bij Medpro voor o.a. prostasol een veelgebruikt natuurlijk middel bij prostaatkanker als alternatief voor hormoontherapie

Update 25 juni 2022: Bron: American Society of Clinical Oncology Genitourinary Cancers Symposium van 17 tot 19 februari 2022

Aanbevolen abstracten gerelateerd aan prostaatkanker en peniskanker door

Dr. Brian Lewis, Assistant Professor of Clinical Medicine in the Department of Hematology and Medical Oncology at Tulane University School of Medicine, New Orleans, and Associate Editor of the PracticeUpdate Center of Excellence Advanced Prostate Cancer, recommends the following abstracts being presented at this year's ASCO Annual Meeting, held June 3 through June 7, 2022, in Chicago and simultaneously online.

Oral Abstract Session: Genitourinary Cancer – Prostate, Testicular, and Penile
Sunday, June 5, 2022; 9:00 AM–12:00 PM EDT

5000 TheraP: 177Lu-PSMA-617 (LuPSMA) versus cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel—Overall survival after median follow-up of 3 years (ANZUP 1603). MS Hofman, L Emmett, S Sandhu, et al

Take-Home Message

Reported here are the overall survival results at a median 3-year follow-up of men with metastatic castration-resistant prostate cancer who progressed after docetaxel and were then randomized to LuPSMA or to cabazitaxel. At a median of 36 months, 77 of 99 men randomized to LuPSMA and 70 of 101 randomized to cabazitaxel had died.
Although overall survival was similar between men receiving LuPSMA and those receiving cabazitaxel, LuPSMA may still be appropriate for men with metastatic disease who progress after docetaxel given the lower rates of adverse events, higher rates of response, and better patient-reported outcomes when compared with cabazitaxel.

5001 Lu-PSMA-617 in PSMA-positive metastatic castration-resistant prostate cancer: Prior and concomitant treatment subgroup analyses of the VISION trial. N Vaishampayan, MJ Morris, BJ Krause, et al

Take-Home Message

The phase III VISION trial involved patients with PSMA-positive metastatic castration-resistant prostate cancer treated with 177Lu-PSMA-617 added to standard of care, showing significantly prolonged radiographic progression–free survival and overall survival. This post hoc analysis looked at survival in the setting of prior and concomitant cancer treatments.
The analysis confirmed the efficacy of 177Lu-PSMA-617 regardless of prior treatment or the standard of care chosen, which indicates that outcomes are driven by disease biology rather than the context of prior and concomitant treatment.

5002 Ga-PSMA-11 PET baseline imaging as a prognostic tool for clinical outcomes to Lu-PSMA-617 in patients with mCRPC: A VISION substudy. P Kuo, J Hesterman, K Rahbar, et al

Take-Home Message

The phase III VISION trial involved patients with PSMA-positive metastatic castration-resistant prostate cancer treated with 177Lu-PSMA-617 added to standard of care, showing significantly prolonged radiographic progression–free and overall survival. This substudy explored the association between imaging data from the pre-enrollment 68Ga-PSMA/PET scans of the patients treated with 177Lu-PSMA-617 and the clinical outcomes of those patients.
The association of clinical outcomes and the PSMA PET parameters was statistically significant. The results of this substudy support the use of 68Ga-PSMA-11 PET/CT to select patients likely to benefit from PSMA-targeted radioligand treatment.

Poster Session: Genitourinary Cancer – Prostate, Testicular, and Penile
Monday, June 6, 2022; 2:15 PM–5:15 PM EDT

5028 Impact of PSMA PET/CT on prostate cancer salvage radiotherapy management: Results from the prospective randomized phase 3 trial [PSMA SRT NCT03582774]. WR Armstrong, AU Kishan, KM Booker, et al

5064 Overall survival (OS) and biomarker results from combat: A phase 2 study of bipolar androgen therapy (BAT) plus nivolumab for patients with metastatic castrate-resistant prostate cancer (mCRPC). MC Markowski, M-E Taplin, RR Aggarwal, et al

5073 Efficacy and safety of relugolix in men with advanced prostate cancer based on baseline body mass index (BMI): A subgroup analysis from the randomized, phase 3 HERO study versus leuprolide (LEU). F Saad, DJ George, M Cookson, et al

Poster Discussion Session: Genitourinary Cancer—Prostate, Testicular, and Penile
Monday, June 6, 2022; 5:30 PM–7:00 PM

5011 Prostate-specific membrane antigen PET response associates with radiographic progression-free survival following stereotactic ablative radiation therapy in oligometastatic castration-sensitive prostate cancer. P Sutera, M Deek, OC Guler

5016 A phase 2 randomized study of oral docetaxel plus ritonavir (ModraDoc006/r) in patients with metastatic castration-resistant prostate cancer (mCRPC). UN Vaishampayan, M Keessen, EI Heath, et al

5018 BRCAAWAY: A randomized phase 2 trial of abiraterone, olaparib, or abiraterone + olaparib in patients with metastatic castration-resistant prostate cancer (mCRPC) with DNA repair defects. MHA Hussain, M Kocherginsky, N Agarwal, et al

Naast verschillende abstracten gepresenteerd op het American Society of Clinical Oncology Genitourinary Cancers Symposium 2022 die we al hebben geplaatst bij artikelen over studies gedaan bij patiënten met prostaatkanker staan in twee verschillende PDF's alle abstracten zoals gepresenteerd bij de onlinebijeenkomst. Het zijn er zoveel dat ik die niet allemaal kan uitzoeken welke wel en niet echt interessant zijn. Maar indien geinteresseerd zie de volgende twee PDF's.

Er staan 64 abstracten voor prostaatkanker met lokale ziekte in deze PDF

En er staan 211 abstracten voor prostaatkanker in gevorderd stadium in deze PDF

ASCO GU 2022, prostaatkanker, aanbevolen abstracten